111 related articles for article (PubMed ID: 10953048)
21. Neuromodulation mediated by the tachykinin NK3-receptor agonist [MePhe7]-neurokinin B in the isolated perfused lung of nonsensitized nonchallenged and ovalbumin-sensitized and -challenged guinea pig.
Corboz MR; Rivelli MA; Fernandez X; Greenfeder S
Exp Lung Res; 2012 Jun; 38(5):233-49. PubMed ID: 22536826
[TBL] [Abstract][Full Text] [Related]
22. Cardiovascular and behavioural effects of centrally administered tachykinins in the rat: characterization of receptors with selective antagonists.
Picard P; Regoli D; Couture R
Br J Pharmacol; 1994 May; 112(1):240-9. PubMed ID: 7518304
[TBL] [Abstract][Full Text] [Related]
23. Tachykinins and tachykinin receptors in human uterus.
Patak E; Candenas ML; Pennefather JN; Ziccone S; Lilley A; Martín JD; Flores C; Mantecón AG; Story ME; Pinto FM
Br J Pharmacol; 2003 Jun; 139(3):523-32. PubMed ID: 12788812
[TBL] [Abstract][Full Text] [Related]
24. Two NK-3 receptor subtypes: demonstration by biological and binding assays.
Nguyen QT; Jukic D; Chrétien L; Gobeil F; Boussougou M; Regoli D
Neuropeptides; 1994 Sep; 27(3):157-61. PubMed ID: 7529376
[TBL] [Abstract][Full Text] [Related]
25. Tachykinin NK3 and NK1 receptor activation elicits secretion from porcine airway submucosal glands.
Phillips JE; Hey JA; Corboz MR
Br J Pharmacol; 2003 Jan; 138(1):254-60. PubMed ID: 12522097
[TBL] [Abstract][Full Text] [Related]
26. Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 1. Identification of the 4-quinolinecarboxamide framework.
Giardina GA; Sarau HM; Farina C; Medhurst AD; Grugni M; Raveglia LF; Schmidt DB; Rigolio R; Luttmann M; Vecchietti V; Hay DW
J Med Chem; 1997 Jun; 40(12):1794-807. PubMed ID: 9191956
[TBL] [Abstract][Full Text] [Related]
27. Isolation and pharmacological characterization of a hamster urinary bladder neurokinin A receptor cDNA.
Aharony D; Little J; Thomas C; Powell S; Berry D; Graham A
Mol Pharmacol; 1994 Jan; 45(1):9-19. PubMed ID: 8302285
[TBL] [Abstract][Full Text] [Related]
28. Tachykinin NK1 receptor subtypes in the rat urinary bladder.
Meini S; Patacchini R; Maggi CA
Br J Pharmacol; 1994 Mar; 111(3):739-46. PubMed ID: 7517327
[TBL] [Abstract][Full Text] [Related]
29. Functional characterization of tachykinin NK1 receptors in the mouse uterus.
Patak E; Pennefather JN; Fleming A; Story ME
Br J Pharmacol; 2002 Dec; 137(8):1247-54. PubMed ID: 12466234
[TBL] [Abstract][Full Text] [Related]
30. Neurokinin B activates arcuate kisspeptin neurons through multiple tachykinin receptors in the male mouse.
de Croft S; Boehm U; Herbison AE
Endocrinology; 2013 Aug; 154(8):2750-60. PubMed ID: 23744641
[TBL] [Abstract][Full Text] [Related]
31. A role for tachykinins in the regulation of human sperm motility.
Ravina CG; Seda M; Pinto FM; Orea A; Fernández-Sánchez M; Pintado CO; Candenas ML
Hum Reprod; 2007 Jun; 22(6):1617-25. PubMed ID: 17437961
[TBL] [Abstract][Full Text] [Related]
32. Molecular and pharmacological characterization of a functional tachykinin NK3 receptor cloned from the rabbit iris sphincter muscle.
Medhurst AD; Hirst WD; Jerman JC; Meakin J; Roberts JC; Testa T; Smart D
Br J Pharmacol; 1999 Oct; 128(3):627-36. PubMed ID: 10516642
[TBL] [Abstract][Full Text] [Related]
33. Molecular and pharmacological characterization of the murine tachykinin NK(3) receptor.
Sarau HM; Feild JA; Ames RS; Foley JJ; Nuthulaganti P; Schmidt DB; Buckley PT; Elshourbagy NA; Brawner ME; Luttmann MA; Giardina GA; Hay DW
Eur J Pharmacol; 2001 Feb; 413(2-3):143-50. PubMed ID: 11226387
[TBL] [Abstract][Full Text] [Related]
34. Effect of YM-44781, YM-44778 and YM-49598, novel tachykinin antagonists, in a drug-induced bladder contraction model.
Choppin A; Groke G; Bringas A; Stepan G; Dillon MP
Pharmacology; 2002 May; 65(2):96-102. PubMed ID: 11937780
[TBL] [Abstract][Full Text] [Related]
35. Tachykinin receptors: a radioligand binding perspective.
Mussap CJ; Geraghty DP; Burcher E
J Neurochem; 1993 Jun; 60(6):1987-2009. PubMed ID: 8388031
[TBL] [Abstract][Full Text] [Related]
36. Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptors.
Malherbe P; Knoflach F; Hernandez MC; Hoffmann T; Schnider P; Porter RH; Wettstein JG; Ballard TM; Spooren W; Steward L
Br J Pharmacol; 2011 Feb; 162(4):929-46. PubMed ID: 21039418
[TBL] [Abstract][Full Text] [Related]
37. Characterization of NK3 receptors in rabbit isolated iris sphincter muscle.
Medhurst AD; Parsons AA; Roberts JC; Hay DW
Br J Pharmacol; 1997 Jan; 120(1):93-101. PubMed ID: 9117105
[TBL] [Abstract][Full Text] [Related]
38. Identification, localization and receptor characterization of novel mammalian substance P-like peptides.
Kurtz MM; Wang R; Clements MK; Cascieri MA; Austin CP; Cunningham BR; Chicchi GG; Liu Q
Gene; 2002 Aug; 296(1-2):205-12. PubMed ID: 12383518
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological analysis of [3H]-senktide binding to NK3 tachykinin receptors in guinea-pig ileum longitudinal muscle-myenteric plexus and cerebral cortex membranes.
Guard S; Watson SP; Maggio JE; Too HP; Watling KJ
Br J Pharmacol; 1990 Apr; 99(4):767-73. PubMed ID: 1694464
[TBL] [Abstract][Full Text] [Related]
40. Neurokinin B activates the formation and bone resorption activity of rat osteoclasts.
Ichiki T; Kuroishi KN; Gunjigake KK; Kobayashi S; Goto T
Neuropeptides; 2011 Jun; 45(3):239-44. PubMed ID: 21514667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
